Goldman Sachs Group Inc X4 Pharmaceuticals, Inc Put Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding XFOR
# of Institutions
107Shares Held
101MCall Options Held
418KPut Options Held
71.7K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$11.2 Million2.01% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$9.89 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$7.05 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.29MShares$5.47 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$4.71 Million0.1% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $45.3M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...